Search

Byline: Beth Snyder Bulik When Eli Lilly signed on to be an Olympic sponsor for the Tokyo Games in 2019, the pandemic was of course yet to come. When COVID-19 [...]

Byline: Beth Snyder Bulik Argenx's dive into rare disease myasthenia gravis (MG) swept three categories in the third annual Fierce Pharma Marketing Awards, which were held Wednesday night. Chosen as [...]

Byline: Beth Snyder Bulik From drab to fab, pharma social media promotions and campaigns are not only getting better but have gotten up to speed with the rest of the [...]

Byline: Beth Snyder Bulik Bristol Myers Squibb's new corporate campaign celebrates transformation--of science, the pharma industry and patients' lives. It's the pharma's first corporate campaign since BMS' own transformation when [...]

Byline: Beth Snyder Bulik Kyowa Kirin wants physicians to make the link between rare cancers that present on the skin to the blood connection underneath. Its new 'Treat the Blood, [...]

Byline: Beth Snyder Bulik Reckitt is recognizing Latino front-line workers with a campaign that celebrates their contributions--and their need to stay healthy. A nurse, a boxing coach and an esthetician [...]

Byline: Beth Snyder Bulik True or false: Pharmaceutical companies are required to send drug ads to the FDA for approval before they're used. It's false--but you'd already know that if [...]

Byline: Beth Snyder Bulik When Bertrand Bodson joined Novartis as its digital chief in 2018, he joined a steady stream of consumer digital leaders flowing into the industry. Now he's [...]

Byline: Beth Snyder Bulik Forget TGI Fridays--this fall there's a new end of week celebration called 'Flu Shot Friday.' Created by Sanofi Pasteur and the American Nurses Association, the campaign [...]

Byline: Beth Snyder Bulik Getting started is often the most difficult part--and that's especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their [...]

Byline: Beth Snyder Bulik Pharma companies today can reach cancer patients and physicians more easily than ever thanks to social media--but should they? Yes, but prepare for both pitfalls and [...]

Byline: Beth Snyder Bulik The ALS Association, known for its Ice Bucket Challenge fundraising, is pushing for a speedy FDA approval of Amylyx's now-pending ALS candidate submission--but is history repeating [...]

Byline: Beth Snyder Bulik Biohaven went all-in on marketing its added preventative indication for oral migraine med Nurtec. And now it's reaping the rewards with doctors. Three months post-approval, 96% [...]

Byline: Beth Snyder Bulik While Regeneron's new awareness campaign comes with a lighthearted pun title, 'Now Eye See' addresses a serious problem for people with diabetes. Diabetic retinopathy is the [...]

Byline: Beth Snyder Bulik With an TV ad that begins 'Welcome to my vagina,' does a brand even need a celebrity to get viewers' attention? Evofem Biosciences isn't taking any [...]

Byline: Beth Snyder Bulik Notoriously laid-back NFL star Rob Gronkowski is looking to score for the telehealth and medication delivery service Hims & Hers Health with messages on social media, [...]

Byline: Beth Snyder Bulik Every morning David Hunt sits down with a cup of coffee and Clubhouse. For an uninterrupted half-hour, he listens and chats with patients, clinicians, payers and [...]

Byline: Beth Snyder Bulik Summer ended much as it began for pharma TV ad spending--Sanofi and Regeneron's anti-inflammatory med Dupixent remains in the top spot. Meanwhile, the perennial No. 1 [...]

Byline: Beth Snyder Bulik Pharma sales reps trying to wedge a foot in the door with doctors face a stark new reality. With more digital interactions than ever before--and no [...]

Byline: Beth Snyder Bulik From Albany to ancient Rome, AMRI's swap of its legacy location name to the stylized industry-relevant Curia was just six months in the making. VSA Partners, [...]

Byline: Beth Snyder Bulik Sanofi removed a website for epilepsy drug Epilim after a consumer complaint. The Medicines and Healthcare products Regulatory Agency (MHRA) investigated (https://www.gov.uk/government/publications/advertising-investigations-may-2021/promotion-of-epilim-sodium-valproate-by-sanofi) the complaint that the [...]

Byline: Beth Snyder Bulik Last week's FDA approval of Pfizer's Comirnaty vaccine boosted consumer confidence among both vaccinated and unvaccinated people. A Harris Poll survey over the weekend found that [...]

Byline: Beth Snyder Bulik Comic books and kids go hand in hand, so Novartis created a custom book to reach kids with rare diseases caused by PIK3CA gene mutations. Specifically [...]

Byline: Beth Snyder Bulik Last summer, many pharma companies joined the crush of brands ditching Facebook ads to press the platform to make changes to stop hate speech. Pfizer, AbbVie [...]

Byline: Beth Snyder Bulik The FDA gets more than a fair share of jabs on social media, but lately its Twitter account has been showing its own spunk. Last week, [...]

Byline: Beth Snyder Bulik Back to school often means meningitis awareness campaigns, but this year GlaxoSmithKline is drawing a distinction between the more common MenACWY vaccine for adolescents and the [...]

Byline: Beth Snyder Bulik GlaxoSmithKline's ovarian cancer awareness campaign began four years ago, but the pharma is doubling down on its education and patient storytelling support during the pandemic. Why? [...]

Byline: Beth Snyder Bulik Pharma's reputation continues to slide, now down to 53% of consumers who still hold a positive view. The decline began after a February high of 62% [...]

Byline: Beth Snyder Bulik Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie--thanks to Nurtec ODT's dual acute-plus-prevention nod and an aggressive digital-first strategy. Digital ads across social [...]

Byline: Beth Snyder Bulik Sun Pharma's latest ad campaign opens in a Savannah, Georgia, diner. Four psoriasis patients on its treatment Ilumya meet for the first time to share coffee [...]

Byline: Beth Snyder Bulik From home improvement shows to Louis Vuitton fashion, 'Make it Yours' slogans have encouraged people to adopt their own style. Now, Moderna is using the tagline [...]

Byline: Beth Snyder Bulik Pharma companies' environmental, social and governance (ESG) efforts skew heavily toward the S, or social, a recent study found. A whopping 77% of pharma ESG efforts [...]

Byline: Beth Snyder Bulik It was the beauty trend of 2020 that no one wanted--maskne. The slang portmanteau referring to acne caused by mask wearing zoomed to the top of [...]

Byline: Beth Snyder Bulik As drug pricing bills bounce around the halls of Congress again, advocates for Medicare negotiation are taking their cause to the TV airwaves. It's not a [...]

Byline: Beth Snyder Bulik Last week, Sesen Bio was finalizing label wording with the FDA on its bladder cancer hopeful Vicineum. This week, the CEO is explaining to investors how [...]

Byline: Beth Snyder Bulik As copycats of complex biologic meds begin to swell into the market and look to unseat their original biologic counterparts, what does that mean for marketing? [...]

Byline: Beth Snyder Bulik Eli Lilly's Olympic sponsorship ended last week with millions of media impressions, bolstered corporate pride and even a gold medal for one of its athletes. Volleyball [...]

Byline: Beth Snyder Bulik Turns out it's going to take more than a successful vaccine response to a global pandemic to make Americans trust pharma companies. A new study from [...]

Byline: Beth Snyder Bulik Bristol Myers Squibb is putting out the welcome mat for young Black college students--and potential pharma industry job candidates. With new partnerships at five historically black [...]

Byline: Beth Snyder Bulik It's a wrap for J&J. A product wrap, that is, as Johnson & Johnson Innovation looks to crowdsource the best ideas in single-dose packaging for its [...]

Byline: Beth Snyder Bulik Johnson & Johnson's Ponvory is the fourth in its class and the ninth branded oral drug in multiple sclerosis, and it hasn't exactly sped out of [...]

Byline: Beth Snyder Bulik Johnson & Johnson's 'Bold' Stelara campaign found a new audience during the televised Olympics. Its strategy? Match athletic perseverance with its message of strength for people [...]

Byline: Beth Snyder Bulik COVID-19 vaccine makers' time in the sun is over, according to one reputation tracker. The reputation boost ignited by the rush to find solutions during the [...]

Byline: Beth Snyder Bulik Sanofi and Regeneron sustained its lead among pharma TV ad spenders in July with anti-inflammatory Dupixent. Former top spender AbbVie on Humira continues to fade as [...]

Byline: Beth Snyder Bulik Longtime digital health marketing leader Ritesh Patel is taking his big-time agency experience to an independent marketing communications shop. In a new role as senior partner [...]

Byline: Beth Snyder Bulik Explaining a complex rare disease is difficult for anyone--now imagine you're a parent trying to explain it to a young child who has cystinosis. Meet Ruby, [...]

Byline: Beth Snyder Bulik SK Life Science's newest digital campaign enlists a professional golfer, a surfer, a football player and a community advocate who have one thing in common. Actually, [...]

Byline: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately--and doctors have had enough. Physicians' trust in the agency [...]

Byline: Beth Snyder Bulik AstraZeneca is taking a cue from lupus patients in launching its freshly approved Saphnelo. Actually, not just a cue--the company turned entire chunks of the marketing [...]

Byline: Beth Snyder Bulik Johnson & Johnson notched a win Friday, with a $50 million talc lawsuit rejected in Illinois--however, tens of thousands of cases are still pending. J&J recently [...]